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Journal Club:
Pregnancy outcome following maternal
exposure to pregabalinmay call for concern
Owing to its anticonvulsive, analgesic, and anxiolytic
properties, pregabalin is used to treat epilepsy, neuro-
pathic pain, and anxiety, respectively. Common side
effects include dizziness, lethargy, and drowsiness.
Pregabalin is a structural analogue of g-aminobutyric
acid and modulates calcium influx on presynaptic
nerve terminals by binding to a subunit on voltage-
gated calcium channels.1
Evidence from animal studies implicates pregaba-
lin as a potential teratogen.2,3 Although human data
are scarce, pregabalin is a Category C drug: risks can-
not be ruled out, but potential benefits may justify
the risks of pregabalin during pregnancy. Suggested
teratogenic mechanisms include reproductive toxic-
ity, skeletal malformation, neural deficits, spontane-
ous abortions, growth retardation, and behavioral
abnormalities. To shed light on this issue, Winterfeld
et al.4 recently investigated adverse pregnancy out-
comes following maternal exposure to pregabalin.
Considering the high prevalence of women of child-
bearing age with neuropathic pain and epilepsy,5,6 it is
important to explore potential teratogenic effects of
first-line treatments. Moreover, as pregnant women
are considered vulnerable, it is difficult to assess risks
during the drug development process. This study
provides an elegant example of an observational study
used to assess fetal risks resulting from exposure to
pregabalin. This work has important implications for
clinical practice guidelines for a range of neurologic
disorders.
HYPOTHESIS AND DESIGN What is the risk of
adverse outcomes following exposure to pregabalin
during pregnancy? To answer this important ques-
tion, Winterfeld et al. performed a multicenter pro-
spective cohort study. A randomized control trial
would not be feasible, which makes the use of a pro-
spective observational cohort appropriate. Further-
more, gathering prospective data reduces recall bias
associated with retrospective studies.
METHODS The study cohort was defined from in-
dividuals within Teratology Information Services
databases in several European countries between
2004 and 2013. Exclusion criteria included the
intake of any known major teratogen or fetotoxi-
cant, as well as exposure to any treatment for malig-
nancy. The primary outcome of the study was the
rate of major birth defects. Two independent and
blinded specialists evaluated the data and major
birth defects were defined according to standard-
ized classifications. Various secondary endpoints
were also defined, such as pregnancy terminations
and rates of live births. The primary exposure of
interest was pregabalin use during pregnancy, with
controls having no exposure to pregabalin or other
anticonvulsants. Logistic regression models were
used to estimate odds ratios (ORs) and 95% confi-
dence intervals (CIs). This statistical approach is
appropriate for binary outcomes (e.g., major birth
defect yes/no) and can be used to control for mul-
tiple confounders such as smoking, alcohol con-
sumption, maternal age, obstetric history, and
concomitant medication use simultaneously.
RESULTS A total of 164 women were exposed to pre-
gabalin. A total of 656 who had not been exposed
served as controls. In the treated cohort, pregabalin
was primarily administered for neuropathic pain,
followed by psychiatric disorders. First trimester prega-
balin exposure occurred in the majority (96%) of the
sample. Overall, higher rates of major birth defects
were found in women exposed to pregabalin during
the first trimester of pregnancy (OR 3.0; 95% CI
1.2–7.9). This elevated risk persisted after adjustment
for potential confounders (listed above). This multivar-
iable analysis was needed to account for baseline differ-
ences noted between the exposed and control group.
For example, significantly higher tobacco use was
noted in women exposed to pregabalin. Moreover,
when examining specific types of major birth defects,
rates of CNS malformations were higher in the prega-
balin group (OR 6.2; 95% CI 1.4–28.3).
INTERPRETATION These findings strongly suggest
that pregabalin should only be considered in women
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of childbearing age by balancing its potential risks to
the child with the benefits to the mother. One major
factor is that the debilitating consequences of the con-
dition may necessitate the use of anticonvulsants (e.g.,
seizures in individuals with epilepsy or severe neuro-
pathic pain).7 In addition to the pain-relieving effects
of pregabalin, a recent study demonstrated a potential
benefit of pregabalin on neurologic motor recovery
among individuals with acute spinal cord injury.8
A study strength is that data were collected pro-
spectively in multiple centers across Europe. The
use of prospective data collection on drug exposures
during pregnancy removes a major source of bias
present in retrospective studies (recall bias). There
are, however, some weaknesses to consider, including
the following:
1. Relatively small sample size. While this was the
largest human study to date exploring pregaba-
lin use during pregnancy, only 164 individuals
were exposed during pregnancy. Compara-
tively, other anticonvulsants have demonstrated
negative effects on pregnancy in much larger
patient cohorts.9
2. There were significant baseline differences in pre-
vious spontaneous abortions between the 2 study
groups. From the data presented, it is unclear
whether or not these women were on pregabalin
at the time of spontaneous abortion.
3. In the pregabalin group, 13% were treated with
another antiepileptic drug. There were also more
complicated medical conditions in the exposed
group. The authors adjusted for concomitant
treatments with other antiepileptic drugs and
some other medications such as antidepressants,
but other unadjusted medications could be impor-
tant confounders. By definition, confounders are
associated with both the exposure and outcome,
but not on the causal pathway between the expo-
sure and outcome.
4. Accordingly, another potential confounder could
be the indications for the anticonvulsant medica-
tions, including pain or epilepsy. Though there is
mixed evidence, there are some data suggesting that
epilepsy can increase the risk of adverse pregnancy
outcomes, even in epileptic women not exposed to
anticonvulsants.10 There is also some evidence to
suggest that stress, which is highly correlated with
pain, can increase the risk of birth defects.11
5. Interaction effects of the drugs were not included
in the analysis. From a pharmacologic point of
view, drug–drug interactions are of great impor-
tance and thus should not be neglected. One
exclusion criterion was maternal exposure to any
known major teratogen or fetotoxicant. However,
some of the reported concomitant drugs, such as
topiramate and valproic acid, are known to be
highly teratogenic (evidence for positive evidence
of risk [Category D] or contraindicated in preg-
nancy [Category X]).12 Taken together with the
aforementioned concerns, it is difficult to com-
pletely discern the teratogenic effects of pregabalin
from other drugs or interaction effects.
6. There was a mixture of methodology used to
ascertain outcomes. Follow-up was obtained via
a telephone interview or mailed questionnaire to
the patient or health care professional. This issue
would be particularly problematic if it differed by
pregabalin use (i.e., nondifferential misclassifica-
tion of outcome).
7. A dose response—one of the criteria for causality
—was not observed, as with several other
teratogens.13
8. Cases and controls were women who themselves
or whose physician contacted one of the teratology
centers. Thus, a selection bias in both groups can-
not be ruled out.
Women of childbearing age contemplating a preg-
nancy and undergoing treatments for neuropathic
pain, epilepsy, or psychiatric disorders represent
a dilemma for treating physicians: is treatment with
pregabalin or other anticonvulsants worth the risk
of harm to the child? With their article, Winterfeld
et al. provide evidence that antiepileptic drugs carry
teratogenic potential. As this is the only current evi-
dence on the matter, pregabalin should only be given
to women of childbearing age after an informed deci-
sion, weighing the benefits and risks. Furthermore, all
women requiring the use of antiepileptics of any kind
should be stringently monitored during pregnancy.
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